Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harriette G C Van Spall

Showing results (1-10 of 246) with videos related to

Pageof 25
Sort By:
Annals of Internal Medicine|December 20, 2017
Review: In HF with preserved EF, β-blockers reduced mortality; drug treatment overall did notHarriette G C Van Spall
Annals of Internal Medicine|January 16, 2013
ACP Journal Club. Review: Case management reduces mortality and HF readmissions in patients with HFHarriette G C Van Spall
Annals of Internal Medicine|March 19, 2019
In patients with previous dilated cardiomyopathy, withdrawal of HF drugs increased relapse at 6 monthsHarriette G C Van Spall
Annals of Internal Medicine|August 19, 2014
ACP Journal Club. Review: Natriuretic peptide-guided therapy reduces mortality more than clinically guided therapy in heart failureHarriette G C Van Spall
Annals of Internal Medicine|October 3, 2022
In HFpEF, the benefit of empagliflozin on a composite of CV death or HF hospitalization at 26 mo did not vary by diabetes statusMarat Fudim, Harriette G C Van Spall
Annals of Internal Medicine|January 6, 2025
In HF with mildly reduced or preserved ejection fraction, finerenone reduced worsening HF or CV death at 32 moMitra Chitsazan, Harriette G C Van Spall,
Annals of Internal Medicine|June 6, 2022
In HF with mitral regurgitation, adding transcatheter mitral valve repair to medical therapy improved renal outcomes at 2 yKevin Damman, Harriette G C Van Spall
Annals of Internal Medicine|September 14, 2020
Vericiguat reduced a composite of CV death or HF hospitalization in patients with HF and reduced LVEFTauben Averbuch, Harriette G C Van Spall
Annals of Internal Medicine|February 18, 2020
Dapagliflozin reduced worsening HF or CV death in HF with reduced ejection fractionKristen Sullivan, Harriette G C Van Spall
Nature Medicine|February 15, 2024
Interventions to enhance digital health equity in cardiovascular careAriana Mihan, Harriette G C Van Spall
Pageof 25

Showing results (1-10 of 246) with videos related to

Sort By:
Pageof 25
Annals of Internal Medicine|December 20, 2017
Review: In HF with preserved EF, β-blockers reduced mortality; drug treatment overall did notHarriette G C Van Spall
Annals of Internal Medicine|January 16, 2013
ACP Journal Club. Review: Case management reduces mortality and HF readmissions in patients with HFHarriette G C Van Spall
Annals of Internal Medicine|March 19, 2019
In patients with previous dilated cardiomyopathy, withdrawal of HF drugs increased relapse at 6 monthsHarriette G C Van Spall
Annals of Internal Medicine|August 19, 2014
ACP Journal Club. Review: Natriuretic peptide-guided therapy reduces mortality more than clinically guided therapy in heart failureHarriette G C Van Spall
Annals of Internal Medicine|October 3, 2022
In HFpEF, the benefit of empagliflozin on a composite of CV death or HF hospitalization at 26 mo did not vary by diabetes statusMarat Fudim, Harriette G C Van Spall
Annals of Internal Medicine|January 6, 2025
In HF with mildly reduced or preserved ejection fraction, finerenone reduced worsening HF or CV death at 32 moMitra Chitsazan, Harriette G C Van Spall,
Annals of Internal Medicine|June 6, 2022
In HF with mitral regurgitation, adding transcatheter mitral valve repair to medical therapy improved renal outcomes at 2 yKevin Damman, Harriette G C Van Spall
Annals of Internal Medicine|September 14, 2020
Vericiguat reduced a composite of CV death or HF hospitalization in patients with HF and reduced LVEFTauben Averbuch, Harriette G C Van Spall
Annals of Internal Medicine|February 18, 2020
Dapagliflozin reduced worsening HF or CV death in HF with reduced ejection fractionKristen Sullivan, Harriette G C Van Spall
Nature Medicine|February 15, 2024
Interventions to enhance digital health equity in cardiovascular careAriana Mihan, Harriette G C Van Spall
Pageof 25